TGFB1 and osteogenesis imperfecta: This therapy has exhibited efficacy in at least two OI mouse models and is currently in clinical trials for OI.(28) Although the above arguments do not address the fact that the G610C mouse rarely suffers from spontaneous fractures like the col1AJrt+, we believe that the G610C model is appropriate for investigating new therapeutics for OI and the differences in efficacy with the TGF‐β antibody observed in the different mouse models might point to different effects of the antibody in different OI types.